(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 July 2021 (29.07.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/148501 A1

(51) International Patent Classification:
*A61K 47/68* (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2021/051263

(22) International Filing Date:
21 January 2021 (21.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/964,180 22 January 2020 (22.01.2020) US
63/085,414 30 September 2020 (30.09.2020) US

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(72) Inventors: **YOU, Fei**; MedImmune, LLC One MedImmune Way, GAITHERSBURG, MARYLAND 20878 (US). **DICKINSON, Niall**; MedImmune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **HOWARD, Philip, Wilson**; MedImmune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(74) Agent: **MCGHEE, Alison**; AstraZeneca Intellectual Property, Milstein Building, Granta Park, Cambridge Cambridge CB21 6GH (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published:**
— *with international search report (Art. 21(3))*

(54) Title: COMPOUNDS AND CONJUGATES THEREOF




(A*)

(57) Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

WO 2021/148501 A1